Sage Journals: Discover world-class research

Abstract

In developing and designing radioimmunotherapy, the selection of the isotope is a major factor. This selection depends on a number of criteria and parameters, affecting usefulness and feasibility.

Usefulness is directly related to the radiological performance of the ionising radiation in relation to tissue and its morphology, with a major distinction between the effects of α and ß-particles (or rays). Usefulness is also directly related to the pharmacodynamic performance of the isotope-carrier (e.g. antibody) complex, where the proper choice of isotope radiodecay halflife is of major importance. Feasibility depends on availability of the components in the isotope-ligand-carrier complex, and also on convenience and safety aspects in the preparation and the handling of the materials as well as in their application in patients.

A comparison is made between the various properties of α-emitting isotopes that have been proposed over a number of years, concluding that the combination ²²⁵Ac- ²¹³Bi deserves serious further attention.

Keywords

Radioimmunotherapy Actinium-225 Bismuth-213 Isotope selection

Get full access to this article

View all access options for this article.

References

Humm

J.L.

, Cobb

L.M.

Non-uniformity of tumor dose in radioimmunotherapy.

J Nucl Med 1990; 31: 75–83.

Wessels

B.W.

, Rogus

R.P.

Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies.

Med Phys 1984; 11: 638–45.

Yorke

E.D.

Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: A predictive model based on mouse pharmacokinetics.

Nucl Med Biol 1991; 18: 827–35.

Fujimori

Modeling analysis of the global and microscopic distribution of immunoglobulin F, F(ab’) and Fab in tumors.

Cancer Res 1989; 49: 5656–63.

Ong

G.L.

, Mattes

M.J.

Penetration and binding of antibodies in experimental human solid tumors grown in mice.

Cancer Res 1989; 49: 4264–73.

Jain

R.K.

, Baxter

L.T.

Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure.

Cancer Res 1988; 48: 7022–32.

Wilbur

D.S.

Potential use of alpha emitting radionuclides in the treatment of cancer.

Antibody Immunoconjugates and Radiopharmaceuticals 1991; 4: 85–97.

Gansow

O.A.

Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelators.

Nucl Med Biol 1991; 4: 369–81.

Geerlings

M.W.

The feasibility of actinum-225 as source of α-particles in radioimmunotherapy.

Nucl Med Comm (in press).

Radionuclides for Radioimmunotherapy: Criteria for Selection

Abstract

Keywords

Get full access to this article

References